Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorRush University Medical Center
About this trial
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Chondroplasty
Synovectomy
Loose body removal
Removal of hardware
Disqualifiers
<18 years at time of enrollment
No diagnosis of ACL tear
ACL repairs
Revision ACL reconstructions
Trial design
Design model
Parallel
Treatments tested in this trial
Losartan
DrugTwo types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.
Placebo
Other interventionThe placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.
Treatment groups
144 Participants
are divided into 2 treatment groupsGroup A: LosartanExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Range of Motion
Range of motion measured from baseline to 12 months
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Rush University Medical Center
Lead sponsor
Arthroscopy Association of North America (AANA)
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: